SCOTT MEDICAL'S ISPAN OPHTHALMIC GASES WILL BE MARKETED BY ALCON SURGICAL
This article was originally published in The Gray Sheet
Executive SummaryAlcon Surgical will market Scott Medical's Ispan Ophthalmic gases under an exclusive worldwide agreement between the two firms. Scott Medical's Ispan C3F8 perfluoropropane gas and Ispan SF6 sulfur hexafluoride gas were both approved by FDA Feb. 25 for use as an aid in the treatment of uncomplicated retinal detachment via pneumatic retinopexy. C3F8 is absorbed by the eye six weeks after injection and SF6 in 10 days. The gases were recommended for approval by FDA's ophthalmic devices panel in April 1991 ("The Gray Sheet" April 22, 1991, I&W-3).
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.